Rationale, Conduct, and Outcome Using Hypofractionated Radiotherapy in Prostate Cancer

Seminars in Radiation Oncology

Volumn 18, Issue 4, 2008, Pages 249-256

  Ritter, Mark ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOCHEMISTRY; CANCER CONTROL; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 49749087577     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.04.007     Document Type: Article

References (38)

1. Bentzen S.M., Overgaard J., Thames H.D., et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 16 (1989) 169-182
2. Thames H.D., and Suit H.D. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 12 (1986) 687-691
3. Haustermans K.M., Hofland I., Van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 1067-1070
4. Pollack A., Zagars G.K., and Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74 (1994) 670-678
5. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
6. Duchesne G.M., and Peters L.J. What is the alpha/beta ratio for prostate cancer?. Rationale for hypofractionated high-dose-rate brachytherapy. [editorial]. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
7. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
8. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
9. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
10. D'Souza W.D., and Thames H.D. Is the a/b ratio for prostate cancer low?. Int J Radiat Biol Oncol Phys 51 (2001) 1-3
11. Wang J.Z., Guerrero M., and Li X.A. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
12. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
13. Fowler J.F., Nahum A.E., and Orton C.G. Point/counterpoint. The best radiotherapy for the treatment of prostate cancer involves hypofractionation. Med Phys 33 (2006) 3081-3084
14. Douglas B.G., and Fowler J.F. The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat Res 66 (1976) 401-426
15. Hall E.J., and Brenner D.J. Extrapolating hypofractionated radiation schemes from radiosurgery data: Regarding Hall et al. IJROBP 21:819-824; 1991 and Hall and Brenner, IJROBP 25:381-385; 1993. Int J Radiat Oncol Biol Phys 32 (1995) 275-276
16. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., et al. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys 32 (1995) 379-390
17. Guerrero M., and Li X.A. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49 (2004) 4825-4835
18. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104
19. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
20. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
21. Collins C.D., Lloyd-Davies R.W., and Swan A.V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3 (1991) 127-132
22. Duncan W., Warde P., Catton C.N., et al. Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 26 (1993) 203-210
23. Read G., and Pointon R.C. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol 63 (1989) 191-195
24. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
25. Akimoto T., Muramatsu H., Takahashi M., et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60 (2004) 1033-1039
26. Tsuji H., Yanagi T., Ishikawa H., et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1153-1160
27. Higgins G.S., McLaren D.B., Kerr G.R., et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 982-989
28. Soete G., Arcangeli S., De Meerleer G., et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. Radiother Oncol 80 (2006) 78-81
29. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 1084-1089
30. Ritter M.A., Forman J.D., Kupelian P.A., et al. A phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys 69 (2007) S174
31. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
32. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
33. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
34. Khoo V.S., and Dearnaley D.P. Question of dose, fractionation and technique: Ingredients for testing hypofractionation in prostate cancer-The CHHiP Trial. Clin Oncol (R Coll Radiol) 20 (2008) 12-14
35. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: What is it, really?. Radiother Oncol 76 (2005) 1-3
36. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007) 1099-1105
37. Pawlicki T., Cotrutz C., and King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol 40 (2007) 395-406
38. Tang C., Loblaw D.A., Cheung P., et al. Condensing external beam radiotherapy to five fractions for low-risk localized prostate cancer. Early results of pHART3 (2008), ASCO 2008 Genitourinary Cancer Symposium, San Francisco, CA 148 February 14-16